Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDFate Therapeutics Inc Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 7 | -$0.30 | -$0.26 | -$0.28 |
| Q2 2026 | 6 | -$0.30 | -$0.28 | -$0.29 |
| Q3 2026 | 3 | -$0.34 | -$0.24 | -$0.29 |
| Q4 2026 | 4 | -$0.33 | -$0.23 | -$0.28 |
| Q1 2027 | 2 | -$0.31 | -$0.21 | -$0.26 |
| Q2 2027 | 2 | -$0.32 | -$0.22 | -$0.27 |
| Q3 2027 | 2 | -$0.33 | -$0.22 | -$0.28 |
| Q4 2027 | 2 | -$0.33 | -$0.23 | -$0.28 |
Fate Therapeutics Inc Earnings Date And Information
Fate Therapeutics Inc last posted its earnings results on Wednesday, May 13th, 2026. The company reported $-0.26 earnings per share for the quarter, topping analysts' consensus estimates of $-0.3 by $0.04. The company had revenue of 1.30 M for the quarter and had revenue of 6.65 M for the year. Fate Therapeutics Inc has generated $-1 earnings per share over the last year ($-1.15 diluted earnings per share) and currently has a price-to-earnings ratio of -1.97. Fate Therapeutics Inc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Fate Therapeutics Inc Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/13/2026 | Q1 2026 | -$0.30 | -$0.26 | 0.04 | $1.49 M | $1.30 M |
| 02/26/2026 | Q4 2025 | -$0.27 | -$0.27 | 0 | $1.34 M | $1.37 M |
| 11/13/2025 | Q3 2025 | -$0.29 | -$0.27 | 0.02 | $1.44 M | $1.74 M |
| 08/12/2025 | Q2 2025 | -$0.35 | -$0.29 | 0.06 | $864.26 K | $1.91 M |
| 05/13/2025 | Q1 2025 | -$0.39 | -$0.32 | 0.07 | $1.07 M | $1.63 M |
| 03/05/2025 | Q4 2024 | -$0.44 | -$0.44 | 0 | $1.37 M | $1.86 M |
| 11/12/2024 | Q3 2024 | -$0.42 | -$0.40 | 0.02 | $1.24 M | $3.07 M |
| 08/13/2024 | Q2 2024 | -$0.47 | -$0.33 | 0.14 | $1.33 M | $6.77 M |
| 05/09/2024 | Q1 2024 | -$0.47 | -$0.47 | 0 | $1.66 M | $1.93 M |
| 02/26/2024 | Q4 2023 | -$0.57 | -$0.45 | 0.12 | N/A | $1.68 M |
| 11/08/2023 | Q3 2023 | -$0.59 | -$0.46 | 0.13 | N/A | $1.94 M |
| 08/08/2023 | Q2 2023 | -$0.58 | -$0.54 | 0.04 | N/A | $933.00 K |
| 05/03/2023 | Q1 2023 | -$0.55 | -$0.09 | 0.46 | N/A | $58.98 M |
| 02/28/2023 | Q4 2022 | -$0.86 | -$0.50 | 0.36 | N/A | $44.36 M |
| 11/03/2022 | Q3 2022 | -$0.93 | -$0.83 | 0.1 | N/A | $14.98 M |
| 08/03/2022 | Q2 2022 | -$0.86 | -$0.79 | 0.07 | N/A | $18.55 M |
| 05/04/2022 | Q1 2022 | -$0.78 | -$0.59 | 0.19 | N/A | $18.41 M |
| 02/28/2022 | Q4 2021 | -$0.68 | -$0.72 | -0.04 | N/A | $17.07 M |
| 11/04/2021 | Q3 2021 | -$0.58 | -$0.45 | 0.13 | N/A | $14.23 M |
| 08/04/2021 | Q2 2021 | -$0.52 | -$0.58 | -0.06 | N/A | $13.41 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Fate Therapeutics Inc Earnings: FAQ's
In the previous quarter, Fate Therapeutics Inc (:FATE) reported $-0.26 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.3 by $0.04.
The conference call for Fate Therapeutics Inc's latest earnings report can be listened to online.
The conference call transcript for Fate Therapeutics Inc's latest earnings report can be read online.
Fate Therapeutics Inc (:FATE) has a recorded annual revenue of $6.65 M.
Fate Therapeutics Inc (:FATE) has a recorded net income of $-136,315,000.Fate Therapeutics Inc has generated $-1.15 earnings per share over the last four quarters.
Fate Therapeutics Inc (:FATE) has a price-to-earnings ratio of -1.97 and price/earnings-to-growth ratio is -0.06.